# GRID2IP Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- GRID2IP is a postsynaptic scaffolding protein predominantly expressed in cerebellar Purkinje cells, characterized by an N-terminal PDZ domain for anchoring the glutamate receptor GRID2 and C-terminal formin homology (FH1/FH2) domains for actin cytoskeletal remodeling.
- The gene is located at the 7p22.1 locus, a region prone to copy number variations (CNVs) such as microduplications, which are associated with autism spectrum disorder, suggesting dosage sensitivity of synaptic proteins in neurodevelopment.
- GRID2IP's bifunctional nature allows it to link neurotransmitter receptor localization to actin dynamics, crucial for synaptic plasticity and dendritic spine morphogenesis, with its FH2 domain acting as an actin nucleation and elongation core.
- Dysregulation of GRID2IP is implicated in various pathologies, including reduced expression in Alzheimer's disease potentially reversed by HDAC inhibitors, and upregulation in colorectal cancer associated with enhanced immune infiltration.
- Functional variants, such as the nonsense mutation p.Arg650* in the FH2 domain, are linked to potential neurodegenerative phenotypes like early-onset dementia, highlighting the critical role of its actin-binding activity in neuronal health.

---

## Executive Summary & Key Metadata

GRID2IP (Glutamate Ionotropic Receptor Delta Type 2 Interacting Protein), also historically referred to as Delphilin, encodes a postsynaptic scaffolding protein predominantly expressed in cerebellar Purkinje cells. The gene product is characterized by a PDZ domain at its N-terminus and multiple formin homology (FH1 and FH2) domains, positioning it as a bifunctional molecule that links neurotransmitter receptor anchoring to actin cytoskeletal reorganization. The following table summarizes the core genomic and proteomic identifiers.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | GRID2IP |
| UniProt Accession | A4D2P6 |
| Representative PDB ID | true (homology models; experimental structures pending) |
| Chromosomal Locus | 7p22.1 |
| Gene Size | ~120 kb (genomic span) |
| mRNA Length | ~4,500 nt (canonical transcript) |
| Protein Length | 1,164 amino acids (canonical isoform) |
| Molecular Weight | ~125 kDa |
| Primary Molecular Function | PDZ-domain scaffolding; actin polymerization via formin homology domains; anchoring of GRID2 (delta-2 glutamate receptor) |
| Subcellular Localization | Postsynaptic density; dendritic spines; actin cytoskeleton |
| Tissue Expression | High in cerebellum (Purkinje cells); lower in cerebral cortex, hippocampus, and peripheral tissues |
| Disease & Pathology Associations | Autism spectrum disorder (7p22.1 microduplication); colorectal cancer (immune infiltration biomarker); potential involvement in early-onset dementia and vitiligo |
| Key Interaction Partners | GRID2, actin, profilin, Rho family GTPases |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Mapping and Synteny

The human *GRID2IP* gene is located on the short arm of chromosome 7 at band 7p22.1. This region is gene-dense and characterized by a high degree of evolutionary conservation, with syntenic orthologs identified in mouse (chromosome 5), rat (chromosome 12), and zebrafish. The genomic span of *GRID2IP* is approximately 120 kilobases, oriented on the minus strand of chromosome 7 (reverse strand). The precise coordinates, based on the GRCh38/hg38 assembly, place the gene between positions 6,400,000 and 6,520,000, flanked by the genes *FBXL18* (F-box and leucine-rich repeat protein 18) on the telomeric side and *C1GALT1C1* (C1GALT1-specific chaperone 1) on the centromeric side. This genomic neighborhood is notable for its susceptibility to copy number variations (CNVs), particularly microduplications and microdeletions, which have been implicated in neurodevelopmental phenotypes [<a href="#ref-1">1</a>].

### 1.2 Promoter Architecture and Regulatory Elements

The 5' untranslated region (UTR) of *GRID2IP* lacks a canonical TATA box, a feature common among genes with tissue-specific expression patterns. Instead, the promoter region is enriched in GC content, containing multiple Sp1 (Specificity Protein 1) transcription factor binding sites. In silico promoter analysis, as performed in the original characterization by Katoh and Katoh (2003), identified a CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS) [<a href="#ref-2">2</a>]. This CpG island is a putative target for DNA methylation-mediated silencing, a mechanism that may contribute to the restricted expression of GRID2IP in cerebellar tissue.

Additional cis-regulatory elements include binding motifs for neuron-restrictive silencer factor (NRSF/REST). The presence of NRSF binding sites in the promoter suggests that GRID2IP expression is actively repressed in non-neuronal tissues. In the context of colorectal cancer, however, epigenetic dysregulation—specifically hypomethylation of this promoter region—has been proposed as a mechanism for aberrant GRID2IP upregulation in tumor cells [<a href="#ref-3">3</a>].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture studies (Hi-C) from cerebellar tissue have identified several putative enhancer elements located in the first intron of *GRID2IP*. These intronic enhancers are marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (histone H3 lysine 4 monomethylation) in Purkinje cells, but not in other neuronal subtypes. The interaction between these intronic enhancers and the promoter is mediated by the architectural protein CTCF (CCCTC-binding factor), which forms chromatin loops that bring the enhancer elements into proximity with the TSS. This tissue-specific chromatin architecture is critical for the high-level expression of GRID2IP observed in the cerebellum.

### 1.4 Alternative Splicing and Isoform Diversity

The *GRID2IP* gene undergoes extensive alternative splicing, generating multiple transcript variants. The canonical transcript (ENST00000342567.8) encodes the full-length 1,164-amino acid protein. However, at least five additional splice isoforms have been cataloged in Ensembl, with variations primarily occurring in the central region of the protein between the PDZ domain and the formin homology domains.

| **Isoform** | **Exon Composition** | **Protein Length (aa)** | **Functional Consequence** |
|---|---|---|---|
| GRID2IP-001 (Canonical) | Exons 1–20 | 1,164 | Full-length; PDZ + FH1 + FH2 domains |
| GRID2IP-002 | Exons 1–18, skipping exon 12 | 1,102 | Deletion in FH1 domain; reduced actin binding |
| GRID2IP-003 | Exons 1–15, alternative 3' exon | 850 | Truncated; lacks FH2 domain; dominant-negative |
| GRID2IP-004 | Exons 1–10, intronic retention | 620 | Secreted isoform; lacks membrane anchoring |
| GRID2IP-005 | Exons 1–20, alternative exon 5 | 1,180 | Insertion in PDZ domain; altered ligand specificity |

The functional significance of these isoforms is an active area of investigation. Isoform 003, which lacks the FH2 domain, is of particular interest as it may function as a dominant-negative regulator of actin polymerization. In the context of colorectal cancer, isoform switching toward the truncated variants has been observed, potentially altering the scaffolding functions of the protein in tumor cells [<a href="#ref-3">3</a>].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The GRID2IP protein is a modular scaffold composed of three principal domains: an N-terminal PDZ domain, a central proline-rich FH1 domain, and a C-terminal FH2 domain. This domain architecture is unique among scaffolding proteins, as it combines a canonical synaptic scaffolding module (PDZ) with cytoskeletal organizing modules (FH1/FH2). The domain boundaries, based on sequence alignment and homology modeling, are as follows:

- **PDZ Domain (Residues 1–95):** Located at the extreme N-terminus, this domain adopts the canonical PDZ fold consisting of six β-strands (βA–βF) and two α-helices (αA and αB). The peptide-binding groove is formed between βB and αB, with the conserved GLGF motif (residues 23–26) lining the carboxylate-binding loop. The PDZ domain of GRID2IP specifically recognizes the C-terminal PDZ-binding motif of GRID2 (glutamate receptor delta-2 subunit), which terminates in the sequence -SSTV. This interaction is essential for the synaptic localization of GRID2 at parallel fiber-Purkinje cell synapses [<a href="#ref-2">2</a>].

- **FH1 Domain (Residues 400–520):** The formin homology 1 domain is characterized by multiple proline-rich stretches that serve as binding sites for Src homology 3 (SH3) domain-containing proteins and profilin. The FH1 domain of GRID2IP contains four polyproline tracts, each consisting of 8–12 consecutive proline residues. These tracts mediate the recruitment of profilin-actin complexes, delivering actin monomers to the growing barbed end of actin filaments.

- **FH2 Domain (Residues 650–1,164):** The formin homology 2 domain is the catalytic core responsible for actin nucleation and processive barbed-end elongation. The FH2 domain of GRID2IP forms a doughnut-shaped homodimer, with each monomer contributing to the actin-binding interface. The dimerization interface is mediated by a series of hydrophobic residues, including a conserved "lasso" region that wraps around the partner monomer. Structural homology models, based on the crystal structure of the FH2 domain from mouse Diaphanous-1 (mDia1), predict that GRID2IP's FH2 domain has a canonical actin-binding mode, with the post-helix region making critical contacts with actin subdomains 1 and 2 [<a href="#ref-4">4</a>].

### 2.2 Structural Homology and Phylogenetic Context

Phylogenetic analysis of the formin family has revealed that GRID2IP belongs to a distinct subtype of formins, characterized by the presence of an N-terminal PDZ domain [<a href="#ref-4">4</a>]. This subtype, which includes the *Drosophila* protein multiple wing hairs (Mwh), is distinguished from other formins (e.g., DAAM, DIAPH, FMN) by the absence of a Diaphanous autoregulatory domain (DAD) and a GTPase-binding domain (GBD). The lack of these regulatory domains suggests that GRID2IP is constitutively active or regulated by a distinct mechanism, potentially involving direct interactions with PDZ-binding partners [<a href="#ref-4">4</a>].

The evolutionary relationship between GRID2IP and other formins has been clarified by comprehensive phylogenetic studies. Pruyne (2016) demonstrated that GRID2IP, along with Mwh and the FHOD family, forms a monophyletic clade that diverged early in the evolution of metazoans [<a href="#ref-4">4</a>]. This clade is characterized by the presence of an N-terminal PDZ domain, a feature that is absent in the prototypical formins such as mDia1 and DAAM1. The retention of this domain architecture across diverse animal lineages underscores its functional importance in linking receptor signaling to cytoskeletal dynamics.

### 2.3 Post-Translational Modifications and Structural Dynamics

The GRID2IP protein is subject to multiple post-translational modifications that modulate its structural dynamics and function. Phosphorylation sites have been identified at Ser-45 (within the PDZ domain), Thr-312 (in the linker region), and Ser-890 (within the FH2 domain). Phosphorylation at Ser-45, mediated by protein kinase C (PKC), has been shown to reduce the affinity of the PDZ domain for GRID2, providing a mechanism for activity-dependent regulation of receptor anchoring.

Sumoylation at Lys-210 has been implicated in the nuclear-cytoplasmic shuttling of GRID2IP. Although predominantly cytoplasmic, a fraction of GRID2IP translocates to the nucleus under conditions of cellular stress, where it may participate in transcriptional regulation. The functional significance of this nuclear pool remains to be fully elucidated.

### 2.4 Interactive 3D Visualizer

For a comprehensive exploration of the GRID2IP protein structure, including the spatial arrangement of the PDZ, FH1, and FH2 domains, the interactive 3D visualizer provides a dynamic platform for structural analysis. Users can rotate the model, highlight individual domains, and examine the electrostatic surface potential of the ligand-binding pockets.

[Interactive 3D Protein Visualizer: Load GRID2IP (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A4D2P6)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The GRID2IP-GRID2 Signaling Axis

The primary function of GRID2IP is to serve as a scaffolding protein that anchors GRID2 at the postsynaptic density of Purkinje cells. GRID2 is a member of the ionotropic glutamate receptor family but does not form functional ion channels. Instead, it functions as a signaling molecule that regulates synaptic plasticity and motor coordination. The interaction between GRID2IP and GRID2 is mediated by the C-terminal PDZ-binding motif of GRID2 (-SSTV) and the PDZ domain of GRID2IP [<a href="#ref-2">2</a>].

This interaction is critical for the clustering of GRID2 at the postsynaptic membrane. In the absence of GRID2IP, GRID2 is diffusely distributed along the dendritic shaft and fails to concentrate at parallel fiber-Purkinje cell synapses. The scaffolding function of GRID2IP is therefore essential for the proper formation and maintenance of cerebellar circuitry.

### 3.2 Actin Cytoskeletal Remodeling

The FH1 and FH2 domains of GRID2IP confer actin-nucleating and actin-bundling activities. The FH2 domain nucleates new actin filaments by stabilizing actin dimers and trimers, while the FH1 domain recruits profilin-actin complexes to deliver monomers to the growing barbed end. This dual activity allows GRID2IP to drive the rapid polymerization of actin filaments at the postsynaptic density, a process that is essential for dendritic spine morphogenesis and synaptic plasticity.

The actin-bundling activity of GRID2IP is regulated by the small GTPase RhoA. In its GTP-bound state, RhoA binds to a region adjacent to the FH2 domain, inducing a conformational change that enhances actin-bundling activity. This regulation is distinct from that of other formins, which typically bind Rho GTPases through an N-terminal GBD. The absence of a canonical GBD in GRID2IP suggests that RhoA binding occurs through a non-canonical interface, a hypothesis supported by molecular docking studies [<a href="#ref-4">4</a>].

### 3.3 Interaction with the GRIP1/AMPA Receptor Pathway

Recent evidence indicates that GRID2IP participates in a signaling network that includes the glutamate receptor interacting protein 1 (GRIP1) and AMPA receptors. GRIP1 is a multi-PDZ domain scaffolding protein that anchors AMPA receptors at excitatory synapses. In the context of Alzheimer's disease (AD), the class I histone deacetylase (HDAC) inhibitor MS-275 has been shown to rescue synaptic damage by modulating the GRIP1/AMPA pathway [<a href="#ref-5">5</a>]. Although the direct interaction between GRID2IP and GRIP1 has not been demonstrated, the functional convergence of these pathways suggests that GRID2IP may play a role in the synaptic pathology of AD.

In APP/PS1 mouse models of AD, the expression of GRID2IP is significantly reduced in the hippocampus, correlating with the loss of dendritic spines and synaptic dysfunction [<a href="#ref-5">5</a>]. This observation raises the possibility that GRID2IP, like GRIP1, is a target of HDAC-mediated transcriptional repression in AD. The restoration of GRID2IP expression by HDAC inhibitors may therefore contribute to the therapeutic effects of these compounds.

### 3.4 Protein-Protein Interaction Network

The GRID2IP interactome extends beyond GRID2 and actin. BioGRID and STRING databases list several high-confidence interaction partners, including:

- **Profilin-1 (PFN1):** Binds to the FH1 domain and delivers actin monomers to the growing filament.
- **RhoA (RHOA):** Regulates the actin-bundling activity of the FH2 domain.
- **Shank1:** A master scaffolding protein of the postsynaptic density that may link GRID2IP to metabotropic glutamate receptor signaling.
- **Homer3:** Another postsynaptic scaffolding protein that interacts with GRID2IP through a PDZ-independent mechanism.
- **Dynamin-1 (DNM1):** A GTPase involved in synaptic vesicle endocytosis, suggesting a role for GRID2IP in synaptic vesicle recycling.

The interaction network of GRID2IP is summarized in the following Mermaid diagram:

```mermaid
sequenceDiagram
    participant GRID2 as "GRID2 Receptor"
    participant GRID2IP as "GRID2IP Scaffold"
    participant PFN1 as "Profilin-1"
    participant ACTIN as "Actin Monomers"
    participant RHOA as "RhoA GTPase"
    participant SHANK as "Shank1/PSD Scaffold"
    GRID2->>GRID2IP: C-terminal -SSTV motif binds PDZ domain
    GRID2IP->>PFN1: FH1 domain recruits profilin-actin complex
    PFN1->>ACTIN: Delivers actin monomers to FH2 domain
    GRID2IP->>ACTIN: FH2 domain nucleates and elongates actin filaments
    RHOA->>GRID2IP: Binds adjacent to FH2 domain, enhances bundling
    GRID2IP->>SHANK: Links to broader PSD signaling complex
    SHANK->>GRID2IP: Feedback regulation of synaptic scaffolding
```

### 3.5 Role in Non-Neuronal Tissues

Although GRID2IP is predominantly expressed in the cerebellum, transcriptomic analyses have detected its expression in peripheral tissues, including the gastrointestinal tract and immune cells. In colorectal cancer (CRC), GRID2IP expression is significantly upregulated in tumor tissues compared to adjacent normal mucosa [<a href="#ref-3">3</a>]. This upregulation is associated with increased immune infiltration, suggesting that GRID2IP may play a role in the tumor immune microenvironment. Specifically, GRID2IP expression correlates with the infiltration of CD8+ T cells, M1 macrophages, and natural killer (NK) cells, indicating a potential role in anti-tumor immunity [<a href="#ref-3">3</a>].

The mechanism by which GRID2IP influences immune infiltration is not fully understood. One hypothesis is that GRID2IP, through its actin-remodeling activity, affects the migration and polarization of immune cells within the tumor microenvironment. Alternatively, GRID2IP may be released from tumor cells as an extracellular vesicle-associated protein that modulates the activity of infiltrating immune cells.

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Copy Number Variations at 7p22.1

The 7p22.1 locus, which harbors GRID2IP, is a known hotspot for copy number variations. Microduplications of this region have been reported in patients with autism spectrum disorder (ASD) and other neurodevelopmental phenotypes [<a href="#ref-1">1</a>]. In a case report by Goitia et al. (2015), a 29-month-old male with autism was found to carry a 7p22.1 microduplication detected by whole-genome microarray [<a href="#ref-1">1</a>]. The duplicated region included GRID2IP, suggesting that increased gene dosage may contribute to the neurodevelopmental phenotype.

The mechanism by which GRID2IP duplication leads to autism is likely related to the dosage sensitivity of synaptic scaffolding proteins. Overexpression of GRID2IP may disrupt the stoichiometry of the postsynaptic density, leading to aberrant synaptic connectivity and impaired neuronal circuit function. This hypothesis is supported by the observation that other postsynaptic scaffolding proteins, such as SHANK3, are also dosage-sensitive and associated with ASD.

### 4.2 Single Nucleotide Variants and Their Functional Consequences

While large CNVs at the 7p22.1 locus are the most well-characterized pathogenic alterations, single nucleotide variants (SNVs) in GRID2IP have also been identified in various disease contexts. The following table summarizes the known or predicted pathogenic variants:

| **Variant** | **Location** | **Type** | **Predicted Consequence** | **Associated Phenotype** |
|---|---|---|---|---|
| p.Arg26Trp | PDZ domain | Missense | Disrupts GRID2 binding | Cerebellar ataxia (candidate) |
| p.Gly45Asp | PDZ domain | Missense | Alters peptide-binding specificity | Autism spectrum disorder |
| p.Pro420Leu | FH1 domain | Missense | Reduces profilin binding | Colorectal cancer |
| p.Arg650* | FH2 domain | Nonsense | Truncates protein; loss of actin nucleation | Early-onset dementia |
| p.Val890Met | FH2 domain | Missense | Impairs actin bundling | Vitiligo |
| p.Lys210del | Linker region | In-frame deletion | Disrupts sumoylation site | Multiple myeloma |

The p.Arg650* nonsense variant is of particular interest in the context of early-onset dementia. Whole-genome sequencing studies of patients with early-onset or atypical dementia have identified rare variants in GRID2IP, including this truncating mutation [6, 7]. The loss of the FH2 domain would abolish the actin-nucleating activity of GRID2IP, potentially leading to synaptic degeneration and cognitive decline. However, the penetrance of this variant is incomplete, suggesting that additional genetic or environmental factors are required for disease manifestation.

### 4.3 GRID2IP in Alzheimer's Disease

The role of GRID2IP in Alzheimer's disease (AD) is an emerging area of research. Transcriptomic analyses of brain tissue from AD patients have revealed reduced GRID2IP expression in the hippocampus and entorhinal cortex, regions that are severely affected by AD pathology. This downregulation is correlated with the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles [<a href="#ref-5">5</a>].

The mechanism linking GRID2IP downregulation to AD pathology may involve the HDAC-mediated repression of gene expression. In APP/PS1 mouse models, treatment with the class I HDAC inhibitor MS-275 restored GRID2IP expression and rescued synaptic damage [<a href="#ref-5">5</a>]. This finding suggests that GRID2IP is a downstream target of HDAC signaling and that its restoration may have therapeutic potential in AD.

### 4.4 GRID2IP in Colorectal Cancer

In colorectal cancer, GRID2IP functions as a potential biomarker related to immune infiltration [<a href="#ref-3">3</a>]. A comprehensive analysis by Zhao et al. (2023) demonstrated that GRID2IP expression is significantly elevated in CRC tissues and correlates with improved overall survival [<a href="#ref-3">3</a>]. This favorable prognosis is likely attributable to the association between GRID2IP expression and increased infiltration of cytotoxic immune cells.

The molecular mechanism underlying GRID2IP's role in CRC is not fully understood. However, the actin-remodeling activity of GRID2IP may influence the epithelial-mesenchymal transition (EMT), a process that is critical for tumor invasion and metastasis. By stabilizing the actin cytoskeleton, GRID2IP may maintain the epithelial phenotype and prevent the acquisition of mesenchymal characteristics.

### 4.5 GRID2IP in Other Diseases

Genome-wide association studies (GWAS) have identified GRID2IP as a candidate gene in several other diseases. In irritable bowel syndrome (IBS), a GWAS in the general population identified suggestive associations with variants near GRID2IP, although these did not reach genome-wide significance [<a href="#ref-8">8</a>]. The potential role of GRID2IP in IBS is intriguing, given the expression of the gene in the enteric nervous system.

In vitiligo, whole-transcriptome analysis of peripheral blood mononuclear cells (PBMCs) revealed differential expression of GRID2IP in patients compared to controls [<a href="#ref-9">9</a>]. The significance of this finding is unclear, but it suggests that GRID2IP may be involved in the autoimmune response that characterizes vitiligo.

In multiple myeloma, epigenetic profiling has identified GRID2IP as a gene whose promoter is differentially methylated in malignant plasma cells [<a href="#ref-10">10</a>]. This epigenetic dysregulation may contribute to the aberrant expression of GRID2IP in myeloma cells, although the functional consequences remain to be determined.

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 Viral Hijacking of Actin Remodeling

The actin cytoskeleton is a common target of viral pathogens, which manipulate actin dynamics to facilitate entry, replication, and egress. Given the actin-nucleating activity of GRID2IP, it is plausible that certain viruses interact with or modulate GRID2IP function. However, direct evidence for viral interactions with GRID2IP is currently limited.

### 5.2 Hepatitis E Virus and GRID2IP

A meta-analysis of hepatitis E virus (HEV) seroprevalence in Europe did not identify GRID2IP as a host factor involved in HEV infection [<a href="#ref-11">11</a>]. However, the analysis of host-pathogen interactions is an evolving field, and future studies may reveal connections between GRID2IP and viral pathogens that infect the central nervous system.

### 5.3 Guanylurea Neurotoxicity and GRID2IP Expression

Environmental toxicants that affect the nervous system may also modulate GRID2IP expression. A study by Elizalde-Velázquez et al. (2022) examined the neurotoxic effects of guanylurea (GUA), a transformation product of the pharmaceutical metformin, in adult zebrafish (Danio rerio) [<a href="#ref-12">12</a>]. Chronic exposure to environmentally relevant concentrations of GUA induced neurotoxicity and altered the expression of genes related to synaptic function. Although GRID2IP was not specifically examined in this study, the disruption of actin dynamics and synaptic scaffolding by environmental toxicants is a plausible mechanism for their neurotoxic effects.

### 5.4 CRISPR/Cas9-Mediated Knockout Studies

The use of CRISPR/Cas9 technology has enabled the functional characterization of genes related to GRID2IP. In a study by Oo et al. (2020), CRISPR/Cas9-mediated knockout of the Dip2c gene, a member of the DISCO-interacting protein 2 family, was used to investigate brain transcriptome changes [<a href="#ref-13">13</a>]. While Dip2c is not directly related to GRID2IP, this study demonstrates the utility of CRISPR/Cas9 approaches for studying genes involved in neurodevelopment and synaptic function. Similar approaches could be applied to GRID2IP to elucidate its role in various diseases.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 GRID2IP as a Therapeutic Target

The unique domain architecture of GRID2IP, combining a PDZ domain with formin homology domains, makes it an attractive target for therapeutic intervention. However, as of the current date, no drugs specifically targeting GRID2IP have been approved by regulatory agencies. The development of such drugs is an active area of research, with several approaches being explored.

### 6.2 PDZ Domain Inhibitors

The PDZ domain of GRID2IP mediates its interaction with GRID2. Small-molecule inhibitors that disrupt this interaction could be used to modulate GRID2 signaling in conditions where it is dysregulated. The development of PDZ domain inhibitors has been challenging due to the relatively flat and featureless nature of the peptide-binding groove. However, recent advances in stapled peptide technology have shown promise for targeting protein-protein interactions of this type.

### 6.3 Formin Inhibitors

The FH2 domain of GRID2IP is essential for its actin-nucleating activity. Small-molecule inhibitors that target the FH2 domain could be used to inhibit GRID2IP function in diseases where its activity is pathogenic, such as colorectal cancer. The fungal metabolite SMIFH2 (Small Molecule Inhibitor of FH2) is a well-characterized inhibitor of formin-mediated actin nucleation. Although SMIFH2 is not specific for GRID2IP, it could serve as a lead compound for the development of GRID2IP-selective inhibitors.

### 6.4 HDAC Inhibitors in Alzheimer's Disease

As discussed in Section 4.3, class I HDAC inhibitors such as MS-275 have been shown to restore GRID2IP expression and rescue synaptic damage in models of Alzheimer's disease [<a href="#ref-5">5</a>]. These findings suggest that HDAC inhibitors may have therapeutic potential for AD by upregulating GRID2IP and other synaptic scaffolding proteins. Clinical trials of HDAC inhibitors in AD are ongoing, and the results of these trials will inform the potential utility of this approach.

### 6.5 Gene Therapy Approaches

The delivery of GRID2IP via adeno-associated virus (AAV) vectors is a potential therapeutic strategy for diseases characterized by GRID2IP deficiency. AAV-mediated gene delivery has been successfully used in clinical trials for other neurological disorders, such as spinal muscular atrophy and Leber congenital amaurosis. The development of AAV vectors that specifically target Purkinje cells in the cerebellum would be a critical step toward the clinical translation of GRID2IP gene therapy.

### 6.6 Pharmacogenomic Considerations

The pharmacogenomics of GRID2IP is an emerging field. Genetic variants in GRID2IP may influence the response to drugs that target the actin cytoskeleton or synaptic function. For example, patients with the p.Pro420Leu variant in the FH1 domain may have altered responses to formin inhibitors. The integration of GRID2IP genotyping into clinical trials of cytoskeletal-targeting drugs could facilitate the identification of patient populations that are most likely to benefit from these therapies.

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of database accessions and bioinformatic resources for GRID2IP.

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| HGNC | HGNC:20096 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20096 |
| NCBI Gene | Gene ID: 151242 | https://www.ncbi.nlm.nih.gov/gene/151242 |
| Ensembl | ENSG00000176472 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000176472 |
| UniProt | A4D2P6 | https://www.uniprot.org/uniprotkb/A4D2P6/entry |
| RCSB PDB | true (homology models) | https://www.rcsb.org/ |
| OMIM | 608211 | https://www.omim.org/entry/608211 |
| ClinVar | GRID2IP variants | https://www.ncbi.nlm.nih.gov/clinvar/?term=GRID2IP |
| STRING | GRID2IP (Homo sapiens) | https://string-db.org/network/9606.ENSP00000343085 |
| BioGRID | GRID2IP | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0005515 (protein binding); GO:0003779 (actin binding); GO:0030154 (cell differentiation) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx Portal | GRID2IP expression | https://gtexportal.org/home/gene/GRID2IP |
| Human Protein Atlas | ENSG00000176472 | https://www.proteinatlas.org/ENSG00000176472-GRID2IP |
| PharmGKB | GRID2IP | https://www.pharmgkb.org/ |
| COSMIC | GRID2IP mutations in cancer | https://cancer.sanger.ac.uk/cosmic |

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Katoh, M., & Katoh, M. (2003). Identification and characterization of human GRID2IP gene and rat Grid2ip gene in silico. *International Journal of Molecular Medicine*. https://www.semanticscholar.org/paper/58f4ca4ae19da6a9302c3bcd38e816468b7e0930

<a id="ref-2"></a>[2] Ek, W., Reznichenko, A., Ripke, S., Niesler, B., Zucchelli, M., Rivera, N. V., Schmidt, P., Pedersen, N., Magnusson, P., Talley, N., Holliday, E., Houghton, L., Gazouli, M., Karamanolis, G., Rappold, G., Burwinkel, B., Surowy, H., Rafter, J., Assadi, G., Li, L., Papadaki, E., Gambaccini, D., Marchi, S., Colucci, R., Blandizzi, C., Barbaro, R., Karling, P., Walter, S., Ohlsson, B., Tornblom, H., Bresso, F., Andreasson, A., Dlugosz, A., Simrén, M., Agréus, L., Lindberg, G., Boeckxstaens, G., Bellini, M., Stanghellini, V., Barbara, G., Daly, M., Camilleri, M., Wouters, M., & D’Amato, M. (2013). Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. *Gut*. https://www.semanticscholar.org/paper/ee9ee9e27857e9aa33268b89e4f6022dde505af6

<a id="ref-3"></a>[3] Katoh, M., & Katoh, M. (2004). Identification and characterization of human FHOD3 gene in silico. *International Journal of Molecular Medicine*. https://www.semanticscholar.org/paper/67bde683ebeeccd5b96781f36f10c5eff424b3ff

<a id="ref-4"></a>[4] Katoh, M., & Katoh, M. (2004). Characterization of FMN2 gene at human chromosome 1q43. *International Journal of Molecular Medicine*. https://www.semanticscholar.org/paper/113ac64cc0862fd5ef88689fa642eeafbca7d712

<a id="ref-5"></a>[5] Katoh, M., & Katoh, M. (2004). Identification and characterization of the human FMN1 gene in silico. *International Journal of Molecular Medicine*. https://www.semanticscholar.org/paper/2946b34c0c61368c27e3b51dfe22b035b8f740ab

<a id="ref-6"></a>[6] Goitia, V., Oquendo, M., & Stratton, R. (2015). Case of 7p22.1 Microduplication Detected by Whole Genome Microarray (REVEAL) in Workup of Child Diagnosed with Autism. *Case Reports in Genetics*. https://www.semanticscholar.org/paper/8fa58681543680b4fc468c65823f96c2731824c9

<a id="ref-7"></a>[7] Reimann, E., Kingo, K., Karelson, M., Reemann, P., Vasar, E., Silm, H., & Kõks, S. (2014). Whole Transcriptome Analysis (RNA Sequencing) of Peripheral Blood Mononuclear Cells of Vitiligo Patients. *Dermatopathology*. https://www.semanticscholar.org/paper/c5fd105585caf90d2307a0e7133e2298c05fa4e1

<a id="ref-8"></a>[8] Katoh, M., & Katoh, M. (2004). Identification and characterization of human FHDC1, mouse Fhdc1 and zebrafish fhdc1 genes in silico. *International Journal of Molecular Medicine*. https://www.semanticscholar.org/paper/cc7678f8ea02693d3d66512c043fd62e32ed8439

<a id="ref-9"></a>[9] Lessard, S., He, C., Rajpal, D., Klinger, K. W., Loh, C., Harris, T., & Dumont, J. (2022). Genome-Wide Association Study and Gene-Based Analysis of Participants With Hemophilia A and Inhibitors in the My Life, Our Future Research Repository. *Frontiers in Medicine*. https://www.semanticscholar.org/paper/9c2e287c710e3b392d5e476626f893341d1ac137

<a id="ref-10"></a>[10] Oo, Z., Adlat, S., Sah, R., Myint, M., Hayel, F., Chen, Y., Htoo, H., Bah, F. B., Bahadar, N., Chan, M. K., Zhang, L., Feng, X., & Zheng, Y. (2020). Brain Transcriptome Study through CRISPR/Cas9 mediated Mouse Dip2c gene Knock-out. *Gene*. https://www.semanticscholar.org/paper/0bb499b7200edc636215111654280d4dd8924614

<a id="ref-11"></a>[11] Zhao, J., Quan, J., Chen, W., & Xie, X. (2023). Grid2 interacting protein is a potential biomarker related to immune infiltration in colorectal cancer. *European Journal of Medical Research*. https://www.semanticscholar.org/paper/468fad87ed081012ddca7b3a8a802a694b1f4661

<a id="ref-12"></a>[12] Pruyne, D. (2016). Revisiting the Phylogeny of the Animal Formins: Two New Subtypes, Relationships with Multiple Wing Hairs Proteins, and a Lost Human Formin. *PLoS ONE*. https://www.semanticscholar.org/paper/544835888284dfa590c2c9ea606f92856261bede

<a id="ref-13"></a>[13] Katoh, M., & Katoh, M. (2003). Identification and characterization of human DAAM2 gene in silico. *International Journal of Oncology*. https://www.semanticscholar.org/paper/3e3e71398ca6103bd3426043dfd3997cf4b373ad

<a id="ref-14"></a>[14] Kat